ArticleNeoplasia (New York, N.Y.)
Aberrant methylation of the maspin promoter is an early event in human breast cancer.
Article in Neoplasia (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic performance of SHOX2 promoter methylation as biomarker for lung cancer identification: A meta-analysis update.Thoracic cancer · 2021Pooled it
- mRNA expression and epigenetic-based role of chromodomain helicase DNA-binding 5 in hepatocellular carcinoma.The Journal of international medical research · 2022Article
- Epigenome editing and epigenetic gene regulation in disease phenotypes.The Korean journal of chemical engineering · 2022Article
- The construction of intrahepatic cholangiocarcinoma model in zebrafish.Scientific reports · 2017Article
- Higher dietary intakes of choline and betaine are associated with a lower risk of primary liver cancer: a case-control study.Scientific reports · 2017Article
- Hierarchical clustering of breast cancer methylomes revealed differentially methylated and expressed breast cancer genes.PloS one · 2015Article
- DNA methylation in ductal carcinoma in situ of the breast.Breast cancer research : BCR · 2013Review
- Regulation of SOD2 in cancer by histone modifications and CpG methylation: closing the loop between redox biology and epigenetics.Antioxidants & redox signaling · 2013Review
- Writing and rewriting the epigenetic code of cancer cells: from engineered proteins to small molecules.Molecular pharmacology · 2013Review
- Article
- miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer.PloS one · 2013Article
- Snail transcription factor negatively regulates maspin tumor suppressor in human prostate cancer cells.BMC cancer · 2012Article
- Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells.Molecular cancer research : MCR · 2011Article
- The redox basis of epigenetic modifications: from mechanisms to functional consequences.Antioxidants & redox signaling · 2011Review
- Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2011Article
- Article
- Increased IKKα expression in the basal layer of the epidermis of transgenic mice enhances the malignant potential of skin tumors.PloS one · 2011Article
- Epigenetic modifications and human disease.Nature biotechnology · 2010Review
- Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients.BMC cancer · 2010Article
- Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization.Cancer research · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The maspin gene functions as a tumor suppressor in human breasts, and its expression is frequently lost during breast cancer progression. In vitro models of human breast cancer indicate that the loss of maspin expression is closely linked to aberrant methylation of the maspin promoter. We conducted a study on 30 archival ductal carcinoma in situ (DCIS) specimens to determine if aberrant methylation of the maspin promoter occurred in vivo, and whether it occurred early in breast cancer evolution. Healthy tissue obtained from reduction mammoplasty was used as normal control. Results from immunohistochemical analysis indicate that maspin expression is lost in a substantial fraction of DCIS specimens (57%). Bisulfite sequencing of DNA isolated from laser capture-microdissected normal and neoplastic ducts showed that loss of maspin expression was often, but not always, linked to aberrant methylation of the maspin promoter, suggesting that other mechanisms, in addition to aberrant methylation, participate and/or cooperate to silence maspin gene expression. Taken together, these results indicate that aberrant methylation of the maspin promoter is an early event in human breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.